Stock Options and Warrants (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Total Stock-based Compensation Expense

Total stock-based compensation expense for the three and nine months ended September 30, 2016 and 2015 was comprised of the following (in thousands):

	Three Months Ended		Three Months Ended		Nine Months Ended		Nine Months Ended
	September 30,		September 30,		September 30,		September 30,
	2016		2015		2016		2015
Cost of sales	$	9	$	6	$	23	$	20
Research and development		128		30		304		121
Selling and marketing		12		8		39		25
General and administrative		146		114		319		334
	$	295	$	158	$	685	$	500

Fair Value of Stock Option Award

The fair value of options granted is estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions for the three and nine months ended September 30, 2016 and 2015:

	Three Months Ended			Three Months Ended			Nine Months Ended			Nine Months Ended
	September 30,			September 30,			September 30,			September 30,
	2016			2015			2016			2015
Significant assumptions (weighted average):
Risk-free interest rate at grant date		0.00	%		1.53	%		1.52	%		1.56	%
Expected stock price volatility		0.00	%		93.85	%		100.00	%		93.81	%
Expected dividend payout		0	%		0	%		0	%		0	%
Expected option life based on management's estimate	0.0 years			5.14 years			6.02 years			5.26 years

Summary of Changes in Options Outstanding and Related Exercise Prices for Shares of Company's Common Stock Options Issued

Transactions involving stock options issued to employees, directors and consultants under the 2006 Plan, the 2010 Plan and outside the plans are summarized below. Options issued have a maximum life of 10 years. The following tables summarize the changes in options outstanding and the related exercise prices for the Company’s common stock options issued:

	Number of					Weighted
	OptionsIssued			Weighted		Average	Aggregate
	Under			AverageExercise		Remaining	Intrinsic
	2006 Plan and			Price Per		Contractual	Value
	2010 Plan			Share		Term	(in thousands)
Outstanding at December 31, 2014		142,244		$	128.47
Granted		76,271		$	3.66
Exercised		—		$	—
Canceled or expired		(17,606	)	$	105.46
Outstanding at December 31, 2015		200,909		$	83.10
Granted		1,346,800		$	3.41
Exercised		—		$	—
Canceled or expired		(65,651	)	$	5.67
Outstanding at September 30, 2016		1,482,058		$	14.11	9.08 years	$	—
Vested and expected to vest at September 30, 2016		1,291,669		$	15.66	9.02 years	$	—
Exercisable at September 30, 2016		175,899		$	92.01	6.05 years	$	—

					Weighted
	Number of		Weighted		Average	Aggregate
	Options Issued		Average Exercise		Remaining	Intrinsic
	Outside		Price Per		Contractual	Value
	the Plan		Share		Term	(in thousands)
Outstanding at December 31, 2014		50,730	$	92.31
Granted		—	$	—
Exercised		—	$	—
Canceled or expired		—	$	—
Outstanding at December 31, 2015		50,730	$	92.31
Granted		—	$	—
Exercised		—	$	—
Canceled or expired		—	$	—
Outstanding, vested and exercisable at September 30, 2016		50,730	$	92.31	3.11 years	$	—

Summary of Changes in Restricted Stock Award Activity

The following table summarizes the changes in restricted stock award activity and the related weighted average exercise prices for the Company’s awards issued:

	Restricted
	Stock Issued
	from the			Weighted
	2006Plan and			Average Grant Date
	2010 Plan			Fair Value
Unvested at December 31, 2014		968		$	24.00
Granted		19,547		$	4.95
Vested		(20,515	)	$	5.81
Forfeited		—		$	—
Unvested at December 31, 2015		—		$	—
Granted		31,611		$	2.31
Vested		(31,611	)	$	2.31
Forfeited		—		$	—
Unvested at September 30, 2016	$	—		$	—

Summary of Outstanding Warrants Related to Warrant Transactions

Share data related to warrant transactions through September 30, 2016 were as follows:

	Common Stock									Common Stock												Common Stock										Price per Warrant
	March 2016 Financing									October 2014 Financing																									Weighted
								Placement											Placement			Skin Care			Jan 2013		Mar 2013		Total						Average
	Series A		Series B			Series C		Agent		Series A			Series B			Series C			Agent			Marketing			Financing		Financing		Warrants			Range			Exercise Price
Outstanding,    December 31, 2014		—		—			—		—		258,519			219,224			258,519			62,045			1,334			33,750		16,667		850,058		$	8.64-300.00		$	10.31
2015
Issued																														—		$		—	$	—
Exercised											(246,108	)		(12,409	)		(258,518	)												(517,035	)	$	1.79-6.72		$	2.40
Forfeited/Cancelled														(206,815	)															(206,815	)	$		11.25	$	11.25
Rounding due to July 29,    2015 reverse stock split											(3	)					(1	)		2										(2	)			—		—
Outstanding,    December 31, 2015		—		—			—		—		12,408			—			—			62,047			1,334			33,750		16,667		126,206		$	1.79-300.00		$	15.82
2016
Issued		3,605,713		3,605,713			3,605,713		342,856																					11,159,995		$	1.75-3.64		$	2.42
Exercised				(569,285	)						(12,408	)								(59,564	)									(641,257	)	$		1.75	$	1.75
Forfeited/Cancelled				(3,036,428	)																		(1,334	)						(3,037,762	)	$	1.75-300.00		$	1.86
Outstanding,    September 30, 2016		3,605,713		—			3,605,713		342,856		—			—			—			2,483			—			33,750		16,667		7,607,182		$	1.75-30.00		$	2.43